A midstage study found that Celgene's experimental drug apremilast was effective in improving symptoms for patients with Behcet's syndrome. According to the study, more patients who took apremilast were free from oral and genital ulcers after 12 weeks of treatment than those who took a placebo.

Full Story:
PharmaTimes (U.K.)

Related Summaries